Cohan, Gary R.
September 1993
Advocate;9/7/93, Issue 637, p39
Presents news concerning AIDS as of September 1993. Ban on the sale of HIV tests in France; Role of AZT in HIV infection; Analysis of AIDS research in the U.S.


Related Articles

  • NAPA sponsors 1999 National HIV Testing Day.  // New York Amsterdam News;06/24/99, Vol. 90 Issue 26, p41 

    Reports that the National Association of People With AIDS (NAPA) has initiated the 1999 National HIV Testing Day campaign. Contact information.

  • Test case. Moss, J. Jennings // Advocate;06/25/96, Issue 710, p33 

    Looks at AIDS activists' opposition to mandatory HIV testing of infants, an aspect of the Ryan White Comprehensive AIDS Resources Emergency Act. Possible threat of mandated HIV testing in the country; AIDS activists' call for the gay community to oppose this regulation.

  • Reducing the gap between the diagnosis and treatment of HIV infection. Singh, Kasha P; Lewin, Sharon R // Medical Journal of Australia;Apr2019, Vol. 210 Issue 6, p261 

    The authors reflect on the benefits of early initiation of antiretroviral therapy (ART) on people with HIV infection, with topics including the study by J. L. McManus and colleagues on the changes in the time from diagnosis to the initiation of ART.

  • Cheaper diagnostics. Kondro, Wayne // CMAJ: Canadian Medical Association Journal;7/12/2011, Vol. 183 Issue 10, pE654 

    The article reports on the initiative to push for cheaper diagnostics of HIV and AIDS testing in poor countries.

  • HIV Type 2 in New York City, 2000-2008. Torian, Lucia V.; Eavey, Joanna J.; Punsalang, Amado P.; Pirillo, Robert E.; Forgione, Lisa A.; Kent, Scott A.; Oleszko, William R. // Clinical Infectious Diseases;12/1/2010, Vol. 51 Issue 11, p1334 

    Background. Antibody cross-reactivity complicates differential diagnosis of human immunodeficiency virus (HIV) type 2 (HIV-2) using standard serologic screening and confirmatory tests for HIV. HIV type 1 (HIV-1) viral load testing does not detect HIV-2. Although HIV-2 is, in general, less...

  • NATIONAL.  // Advocate;12/31/91, Issue 593, p22 

    Presents news briefs concerning AIDS in the U.S. Centers for Disease Control's plan to develop a list of medical procedures that physicians who test positive for HIV antibodies would be forbidden to perform; Effectiveness of the AZT drug; Allocation of funds to AIDS programs.

  • Guidelines for Early AZT Use. Helquist, Michael // Advocate;4/10/90, Issue 548, p24 

    Reports that a national board of AIDS specialists in the U.S. has issued guidelines for the testing, medical evaluation, and long-term drug therapy of people in the early stages of HIV infection. Emphasis on the importance of pre- and post-test counselling; Recommended daily dose of AZT.

  • An Ugly 'Spin' on AZT. Byron, Stuart // Advocate;12/5/89, Issue 539, p53 

    Explores controversy concerning the AIDS drug, AZT. Celia Farber's article 'Sins of Omission: The AZT Scandal' published in the November issue of 'Spin'; Sensational series of articles in the 'New York Native' concerning AZT trials; AIDS study questioning the effectiveness of AIDS.

  • Brokers Find Rough Trade In New York. Freiberg, Peter // Advocate;10/24/89, Issue 536, p12 

    Reports on the protest action taken by a group of New York City AIDS activists at the trading floor of the New York Stock Exchange. High cost of AZT, a drug that is believed to be effective in slowing the course of AIDS in some people.

  • Double blind dose-response study of zidovudine in AIDS and advanced HIV infection.  // BMJ: British Medical Journal (International Edition);1/4/92, Vol. 304 Issue 6818, p13 

    Investigates the efficacy and side effects of zidovudine in patients with AIDS. Significance of death rates; Development of neuropathic side effects with higher dosage; Importance of dose-response studies on drug development; Effects the drug on the dementia complex.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics